Agilent Technologies Awards Two Integrated-Biology Research Grants
News Oct 20, 2011
Agilent Technologies Inc. (NYSE: A) has announced the winners of the 2011 eMerging Insights grant program: Dr. Michael J. MacCoss of the University of Washington and Dr. Peter J. Park of Harvard University. Each will be awarded $75,000 toward their ongoing research on open source data-integration tools.
The first grant, for “Validating Protein Pathway Information: Integrating Proteomic Data with Transcriptomic or Metabolomic Data Sets,” was awarded to MacCoss, an assistant professor in the department of genome sciences at the University of Washington. His research is focused on stable isotope and mass spectrometry methods for studying biology at the molecular, cellular, and whole organism level. MacCoss’ lab developed and maintains the Skyline Targeted Proteomics Environment —a widely used, open-source proteomics software platform for building selected reaction-monitoring/multiple reaction-monitoring methods and analyzing the resulting data.
For the eMerging Insights Program, MacCoss and his team will expand Skyline’s capabilities to allow seamless integration with Agilent’s GeneSpring software. Their vision is to update Skyline to allow researchers to first analyze genome-wide association data, gene expression data, or discovery proteomics and metabolomics data using GeneSpring, and then use this information to rapidly generate a list of candidate proteins for further verification by mass spectrometry.
“We are really excited to work with Agilent to improve the integration of their gene expression tools with our targeted proteomics software, Skyline,” MacCoss said. “These developments should expedite the selection of protein targets and the measurement of those targets by tandem mass spectrometry.”
The second grant, for “Modeling Disease Progression: Combining Gene Expression and Copy Number Variation Data,” was awarded to Dr. Park, an associate professor of pediatrics at the Center for Biomedical Informatics at Harvard Medical School. He has developed a method, based on biclustering, to identify genes whose expression is driven by copy number variations (CNV).
For the eMerging Insights Program, Park and his team will extend this work to compare tumors at different grades, to gain insight into how CNV and gene expression drive disease progression. They will also develop this tool into a browser-based application that will allow biologists and clinicians to perform similar analyses with their own data sets and easily visualize and interpret the results. The proposed tool will enable accurate and robust integration of CNV and gene expression data, allowing the research community to gain greater insight into how changes at the sequence level affect gene expression and disease progression.
“This grant provides a wonderful opportunity for us to transform our bioinformatic algorithms and visualization techniques into tools that will be useful to the community,” Park said.
“Agilent solutions enable genomic, metabolomic, proteomic and other important life science measurements,” said Gustavo Salem, vice president and general manager of Agilent’s Biological Systems Division. “Our recognition and support of the work of Dr. MacCoss and Dr. Park with these eMerging Insights grants reflects our confidence in their work and our commitment to advancing bioinformatic solutions that relate these different aspects of biological systems.”
Protein Discovery Could Lead to Better Diagnosis of StressNews
Researchers have found a protein that is present in people while they are in stressful situations. The discovery could lead to identifying new ways to predict, diagnose and treat stress.READ MORE
Tiny “Tornado” Boosts Performance of Electrospray Ionization Mass SpectrometryNews
Known as Dry Ion Localization and Locomotion (DRILL), the new device creates a swirling flow that can separate electrospray droplets depending on their size.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Comments | 0 ADD COMMENT
11th Edition of International Conference on Proteomics 2018
Mar 22 - Mar 23, 2018